195 related articles for article (PubMed ID: 25688517)
1. Long-term response to pazopanib in an elderly man with mRCC. A case report.
D'Aniello C; Cavaliere C; Pisconti S; Facchini G
Tumori; 2014; 100(6):e305-8. PubMed ID: 25688517
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapy in renal carcinoma: a case of long-term effect with complete control of toxicity.
Conforti S; Ceniti S; Conforti L; Turano S; Minardi S; Palazzo S
Tumori; 2014; 100(6):e293-7. PubMed ID: 25688514
[TBL] [Abstract][Full Text] [Related]
3. First-line pazopanib in intermediate- and poor-risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial.
Staehler M; Panic A; Goebell PJ; Merling M; Potthoff K; Herrmann E; de Geeter P; Vannier C; Hogrefe C; Marschner N; Grünwald V
Int J Cancer; 2021 Feb; 148(4):950-960. PubMed ID: 32738823
[TBL] [Abstract][Full Text] [Related]
4. Successful re-administration of Pazopanib in a patient with metastatic renal cell carcinoma and a history of Pazopanib-induced nephrotic syndrome: a case report.
Jeon SY; Lee NR; Yim CY
BMC Nephrol; 2019 Jan; 20(1):1. PubMed ID: 30606155
[TBL] [Abstract][Full Text] [Related]
5. [First Hungarian experience with pazopanib therapy for patients with metastatic renal cancer].
Maráz A; Bodrogi I; Csejtei A; Dank M; Géczi L; Küronya Z; Mangel L; Petrányi A; Szûcs M; Bodoky G
Magy Onkol; 2013 Sep; 57(3):173-6. PubMed ID: 24107823
[TBL] [Abstract][Full Text] [Related]
6. [Pazopanib for treatment of renal cell carcinoma and soft tissue sarcomas].
Brotelle T; Bay JO
Bull Cancer; 2014 Jun; 101(6):641-6. PubMed ID: 24977453
[TBL] [Abstract][Full Text] [Related]
7. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.
Sternberg CN; Hawkins RE; Wagstaff J; Salman P; Mardiak J; Barrios CH; Zarba JJ; Gladkov OA; Lee E; Szczylik C; McCann L; Rubin SD; Chen M; Davis ID
Eur J Cancer; 2013 Apr; 49(6):1287-96. PubMed ID: 23321547
[TBL] [Abstract][Full Text] [Related]
8. Case report of a long-surviving man with metastatic renal cell carcinoma treated with pazopanib.
Ratta R; Santini D
Tumori; 2014; 100(2):e59-62. PubMed ID: 24852879
[TBL] [Abstract][Full Text] [Related]
9. Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?
Grassi P; Verzoni E; Ratta R; Porcu L; Prisciandaro M; Mennitto A; Calareso G; de Braud F; Procopio G
Drugs R D; 2017 Sep; 17(3):461-467. PubMed ID: 28801802
[TBL] [Abstract][Full Text] [Related]
10. Pazopanib for Metastatic Renal Cell Carcinoma: A Registry-based Analysis of 426 Patients.
Poprach A; Fiala O; Chloupkova R; Melichar B; Lakomy R; Petrakova K; Zemanova M; Kopeckova K; Slaby O; Studentova H; Kopecký J; Kiss I; Finek J; Dusek L; Buchler T
Anticancer Res; 2018 Jan; 38(1):449-456. PubMed ID: 29277808
[TBL] [Abstract][Full Text] [Related]
11. Good tolerability, long-term survival and easy management of side effects in a patient with metastatic renal cell carcinoma treated with pazopanib.
Frascaroli M; Di Cesare P
Tumori; 2014; 100(6):e301-4. PubMed ID: 25688516
[TBL] [Abstract][Full Text] [Related]
12. A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma.
Kim MJ; Park SH; Lee JL; Lee SH; Lee SJ; Lim HY
BMC Urol; 2016 Aug; 16(1):46. PubMed ID: 27484998
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of patients with metastatic renal cell carcinoma treated with pazopanib in daily clinical practice: a single institution experience.
Ricotta R; Di Bella S
Tumori; 2014; 100(3):e87-91. PubMed ID: 25076258
[TBL] [Abstract][Full Text] [Related]
14. Pazopanib in Renal Cell Carcinoma Dialysis Patients: A Mini-Review and a Case Report.
Bersanelli M; Facchinetti F; Tiseo M; Maiorana M; Buti S
Curr Drug Targets; 2016; 17(15):1755-1760. PubMed ID: 26758665
[TBL] [Abstract][Full Text] [Related]
15. Prospective observational study on Pazopanib in patients treated for advanced or metastatic renal cell carcinoma in countries in Asia Pacific, North Africa, and Middle East regions: PARACHUTE study.
Erman M; Biswas B; Danchaivijitr P; Chen L; Wong YF; Hashem T; Lim CS; Karabulut B; Chung HJ; Chikatapu C; Ingles S; Slimane K; Kanesvaran R
BMC Cancer; 2021 Sep; 21(1):1021. PubMed ID: 34521387
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.
Xie M; He CS; Huang JK; Lin QZ
Eur J Cancer; 2015 Mar; 51(5):595-603. PubMed ID: 25618828
[TBL] [Abstract][Full Text] [Related]
17. Effect of Concomitant pH-Elevating Medications with Pazopanib on Progression-Free Survival and Overall Survival in Patients with Metastatic Renal Cell Carcinoma.
McAlister RK; Aston J; Pollack M; Du L; Koyama T; Chism DD
Oncologist; 2018 Jun; 23(6):686-692. PubMed ID: 29487220
[TBL] [Abstract][Full Text] [Related]
18. Cardiac metastasis from renal cell carcinoma successfully treated with pazopanib: impact of TKIs' antiangiogenic activity.
Schinzari G; Monterisi S; Signorelli D; Cona MS; Cassano A; Danza F; Barone C
Tumori; 2014; 100(6):e298-300. PubMed ID: 25688515
[TBL] [Abstract][Full Text] [Related]
19. Experience with pazopanib in the treatment of metastatic renal cell carcinoma: a monocentric experience.
Gernone A
Tumori; 2014; 100(4):165e-8e. PubMed ID: 25296611
[TBL] [Abstract][Full Text] [Related]
20. Initial experience with first-line pazopanib in the treatment of metastatic renal cell carcinoma: A single institution data.
Joshi A; Agarwala V; Ramaswamy A; Noronha V; Patil VM; Menon S; Popat P; Sable N; Prabhash K
Indian J Cancer; 2016; 53(4):575-578. PubMed ID: 28485355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
